Long-term study for people already taking pelabresib
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already in a study taking the drug pelabresib and your doctor says it's helping you.
- You are willing to keep coming to study visits and follow all procedures.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use highly effective birth control for 6 months after treatment.
- If you are a man, you must use highly effective birth control and not donate sperm for about 3 months after treatment.
- You cannot be pregnant or breastfeeding, and you cannot have any serious medical problems that would make the study unsafe.
- You agree not to take other cancer treatments or drugs that could interfere with pelabresib during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
This trial tests how the drug pelabresib works in people with advanced cancer who also have mild to severe liver problems. It aims to understand safety and how the drug moves through the body.
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
This study allows people who are already taking alpelisib in another Novartis trial to continue receiving it long-term. The goal is to keep giving the drug to those who are benefiting from it, and to track safety over a longer period.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.